Увійти

Готові списки джерел за темами / 342.72 + 340.15(043.2)

Зміст

Статті в журналах

Добірка наукової літератури з теми "342.72 + 340.15(043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "342.72 + 340.15(043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "342.72 + 340.15(043.2)"

1

Kivitz, A., A. F. Wells, J. Ignacio Vargas, et al. "POS0685 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 620–21. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1819.

Повний текст джерела

Анотація:

BackgroundUpadacitinib (UPA) was previously evaluated in two Phase 2, randomized, controlled trials (RCTs) in patients (pts) with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor inhibitors (BALANCE-1) or methotrexate (BALANCE-2).ObjectivesTo assess the final safety and efficacy of UPA in BALANCE-EXTEND, a 312-week open-label extension (OLE) enrolling pts who completed either BALANCE-1 or BALANCE-2.MethodsAll pts initially received UPA 6 mg twice daily (BID). Increase to 12 mg BID was required for pts with <20% improvement in swollen or tender joint counts (S/TJC)

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Hebden, R. A., M. E. Todd, and J. H. McNeill. "Relationship between atrial granularity and release of atrial natriuretic factor in rats with diabetes mellitus." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 257, no. 4 (1989): R932—R938. http://dx.doi.org/10.1152/ajpregu.1989.257.4.r932.

Повний текст джерела

Анотація:

We examined the effect of a 25% blood volume expansion on the release of atrial natriuretic factor (ANF) in conscious Wistar rats (13-15 wk old) injected 6 wk earlier with streptozotocin (55 mg/kg iv, diabetic) or saline (1 ml/kg iv, control). The diabetic rats demonstrated a significant (P less than 0.05) resting hypotension (132 +/- 2/91 +/- 1 mmHg, systolic/diastolic) and bradycardia (340 +/- 5 beats/min) compared with the controls (145 +/- 2/98 +/- 2 mmHg, 377 +/- 8 beats/min). Resting plasma immunoreactive (IR) ANF levels were significantly (P less than 0.05) elevated in the diabetic rats

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Dombret, Hervé, Alexandra Coelho, Laurène Fenwarth, et al. "Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study." Blood 144, Supplement 1 (2024): 2424. https://doi.org/10.1182/blood-2024-207226.

Повний текст джерела

Анотація:

Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Less-intensive options, like the AZA-VEN combination, are used in older/unfit patients. However, while treatments and indications are standardized, their choice is not, depending on often-subjective factors. This makes observational studies so important to describe the real-life management and outcomes of AML patients. Methods. In 2022, the ALFA group initiated a 2-cohort (newly diagnosed, relapsed/refractor

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Li, Bing, Jinqin Liu, Shiqiang Qu, et al. "Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome." Blood 126, no. 23 (2015): 2874. http://dx.doi.org/10.1182/blood.v126.23.2874.2874.

Повний текст джерела

Анотація:

Abstract Introduction: The myelodysplastic syndromes (MDS) are a group of clonal diseases derived from hematopoietic stem cells (HSC). Colony-forming unit cell (CFU-C) assay is an effective method to study the number and the function of HSC in vitro. In this study, we focus on the characteristics and the prognostic value of CFU-C in patients with MDS. Patients and Method: CFU-C assays were performed according to the protocol of MethoCultTM H4435 Enriched (STEMCELL Technologies). A colony was defined as an aggregate of >40 cells. Clusters consisted of 4 to 40 cells. 560 consecutive newly-dia

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Overcash, J. Scott, William O’Riordan, Megan Quintas, Laura Lawrence, Carol Tseng, and Sue Cammarata. "470. Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)." Open Forum Infectious Diseases 6, Supplement_2 (2019): S230. http://dx.doi.org/10.1093/ofid/ofz360.543.

Повний текст джерела

Анотація:

Abstract Background Delafloxacin (DLX), an IV/oral anionic fluoroquinolone antibiotic, is approved for the treatment of ABSSSI including those due to MRSA and Gram-negative pathogens including P. aeruginosa. Two global phase 3 ABSSSI trials included patients with substance abuse including IV drugs. Methods Two multicenter, double-blind, double-dummy trials of adults with ABSSSI randomized patients 1:1 to receive either DLX monotherapy or vancomycin 15 mg/kg + aztreonam (VANAZ) for 5–14 days. Study 302 used DLX 300 mg BID IV only; study 303 used DLX 300 mg BID IV for 3 days with a mandatory bli

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Vieira Bento Silva, A. D., M. H. Fernandes Lourenco, S. Ramiro, et al. "POS0678 PERFORMANCE OF CLINICAL, LABORATORY AND IMAGING FEATURES FOR THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS - A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 621.1–621. http://dx.doi.org/10.1136/annrheumdis-2023-eular.108.

Повний текст джерела

Анотація:

BackgroundThe Berlin algorithm for axial spondyloarthritis (axSpA) diagnosis was developed more than 15 years ago. New evidence suggests that the diagnostic performance of some SpA features might not be as good as initially thought.ObjectivesTo review the evidence on the performance of SpA features for axSpA diagnosis.MethodsSystematic literature review and meta-analysis of studies (2004-2021) reporting data on ≥1 SpA feature. The population was defined as adults (≥16 years) with a suspicion or definite clinical diagnosis of axSpA. The diagnostic performance of each SpA feature was tested agai

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Adinolfi, A., S. Sirotti, G. Sakellariou, et al. "POS1141 ASSESSING RELEVANT JOINTS FOR MONITORING CPPD DISEASE: A SYSTEMATIC LITERATURE REVIEW OF IMAGING TECHNIQUES BY THE OMERACT ULTRASOUND – CPPD SUBGROUP." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 850.1–850. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3153.

Повний текст джерела

Анотація:

Background:Imaging has been extensively used for the Calcium Pyrophosphate Deposition Disease (CPPD) diagnosis but the prevalence of joint calcifications at imaging in CPPD patients has not been thoroughly assessed.Objectives:This systematic literature review (SLR) is aimed to estimate the prevalence of calcium crystal deposition in peripheral joints by imaging in suspected or definite CPPD patients to establish relevant joints for CPPD monitoringMethods:After defining PICOs, Pubmed and Embase were searched from inception to October 2020 for identifying studies that evaluated the use of Conven

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Herrero-Morant, A., J. Loricera, I. Ferraz-Amaro, et al. "AB0707 PREDICTIVE FACTORS OF RELAPSE IN GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1557.2–1558. http://dx.doi.org/10.1136/annrheumdis-2023-eular.4399.

Повний текст джерела

Анотація:

BackgroundTocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trials with TCZ in GCA was performed with intravenous (iv) TCZ in a phase 2 trial[1], and with subcutaneous (sc) TCZ in the phase 3 GiACTA[2].There is general agreement on the initial/maintenance dose, but duration of TCZ therapy is not well established. In GiACTA trial, after one year on TCZ, most patients had GCA relapse after withdrawal.ObjectivesTo assess the predictive factors of relapse in GCA in a clinical practice scenario.MethodsMulticentre observational study of 471 patients wit

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Sakamoto, Tomohiro, Taichi Matsubara, Takayuki Takahama, et al. "Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer." JAMA Network Open 6, no. 12 (2023): e2347700. http://dx.doi.org/10.1001/jamanetworkopen.2023.47700.

Повний текст джерела

Анотація:

ImportanceBiomarker testing for driver mutations is essential for selecting appropriate non–small cell lung cancer (NSCLC) treatment but is insufficient.ObjectiveTo investigate the status of biomarker testing and drug therapy for NSCLC in Japan for identifying problems in treatment.Design, Setting, and ParticipantsThe REVEAL cohort study included retrospective data collection and prospective follow-up from 29 institutions across Japan. Of 1500 patients diagnosed with advanced or recurrent NSCLC between January 1 and March 18, 2021, 1479 were eligible. Cases recognized at the wrong clinical sta

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Serdán Ruiz, David Leonardo, Katterine Kariuxy Vásquez Bone, and Ana Emperatriz Yupa Pallchisaca. "LAS INFECCIONES EN EL TRACTO URINARIO EN LA MUJER EMBARAZADA Y SU INCIDENCIA EN LA MORBILIDAD Y MORTALIDAD DE NEONATOS." Universidad Ciencia y Tecnología 24, no. 106 (2020): 102–8. http://dx.doi.org/10.47460/uct.v24i106.402.

Повний текст джерела

Анотація:

La infección del tracto urinario de origen bacteriano es una patología frecuente en la mujer embarazada. Constituye un importante factor de riesgo asociado con el desarrollo de sepsis neonatal. La sepsis neonatal es una infección invasiva generalmente acompañada de bacteriemia que se presenta en el neonato en el primer mes de vida. Es una de las causas principales de morbilidad y mortalidad neonatal. El objetivo de esta investigación fue mostrar la relación entre la infección en el tracto urinario en la madre embrazada y la morbilidad y mortalidad del neonato. Se realizó un estudio de casos y

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!